Needham & Company LLC decreased their price objective on shares of Cytokinetics (NASDAQ:CYTK) from $25.00 to $15.00 in a research note issued on Monday, AnalystRatingsNetwork.com reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price objective would suggest a potential upside of 230.40% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at MLV & Co
downgraded shares of Cytokinetics from a “buy” rating to a “hold” rating in a research note on Friday, April 25th. They now have a $5.00 price target on the stock, down previously from $26.00. Separately, analysts at Piper Jaffray downgraded shares of Cytokinetics from an “overweight” rating to a “neutral” rating in a research note on Friday, April 25th. They now have a $7.00 price target on the stock, down previously from $18.00. Finally, analysts at Roth Capital initiated coverage on shares of Cytokinetics in a research note on Wednesday, March 5th. They set a “buy” rating and a $25.00 price target on the stock. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. Cytokinetics currently has a consensus rating of “Buy” and an average price target of $12.20.
Cytokinetics (NASDAQ:CYTK) opened at 4.54 on Monday. Cytokinetics has a one year low of $4.30 and a one year high of $14.28. The stock’s 50-day moving average is $9.50 and its 200-day moving average is $8.0. The company’s market cap is $163.8 million.
Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.21 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.08) by $0.29. The company had revenue of $24.30 million for the quarter, compared to the consensus estimate of $19.14 million. Analysts expect that Cytokinetics will post $-1.26 EPS for the current fiscal year.
Cytokinetics, Incorporated (NASDAQ:CYTK) is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.